Regencell Bioscience Stock (NASDAQ:RGC)


ForecastOwnershipChart

Previous Close

$18.83

52W Range

$9.39 - $81.23

50D Avg

$26.49

200D Avg

$22.44

Market Cap

$8.45B

Avg Vol (3M)

$129.96K

Beta

1.64

Div Yield

-

RGC Company Profile


Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

HK

Employees

12

IPO Date

Jul 16, 2021

Website

RGC Performance


Peer Comparison


TickerCompany
AXSMAxsome Therapeutics, Inc.
ATRAptarGroup, Inc.
RYTMRhythm Pharmaceuticals, Inc.
ABVXAbivax S.A.
GRFSGrifols, S.A.
MASIMasimo Corporation
NUVLNuvalent, Inc.
MRUSMerus N.V.
STVNStevanato Group S.p.A.
CYTKCytokinetics, Incorporated